未登录 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study 高风险、早期、三阴性乳腺癌患者对新辅助培美曲塞联合化疗反应的分子决定因素：开放标签、多队列1b期KEYNOTE-173研究的探索性分析 Dent, Rebecca; Cortes, Javier; Park, Yeon Hee; Munoz-Couselo, Eva; Kim, Sung-Bae; Sohn, Joohyuk; Im, Seock-Ah; Holgado, Esther; Foukakis, Theodoros; Kuemmel, Sherko; Yearley, Jennifer; Wang, Anran; Nebozhyn, Michael; Huang, Lingkang; Cristescu, Razvan; Jelinic, Petar; Karantza, Vassiliki; Schmid, Peter 分享 收藏
分享 收藏
A phase III, randomized study of adjuvant sacituzumab tirumotecan (sac-TMT) plus pembrolizumab vs treatment of physician's choice (TPC) in patients with TNBC who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery 一项关于辅助治疗中sacituzumab tirumotecan（sac-TMT）联合pembrolizumab与医生选择治疗方案（TPC）对比的III期随机研究，研究对象为接受新辅助治疗且手术中未达到病理完全缓解（pCR）的TNBC患者。 Dent, R. A.; Hui, R.; Park, Y. H.; Schmid, P.; Wei, J.; Mejia, J. A.; Pan, W.; Cortes, J.; McArthur, H. L. 分享 收藏
Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptorepositive (HR plus ) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06) 人表皮生长因子受体2（HER2）-低和HER2-超低状态在激素受体阳性（HR plus）转移性乳腺癌（mBC）患者（pts）肿瘤中的确定（DESTINY-Breast06 [DB-06]）。 Salgado, R. F.; Bardia, A.; Curigliano, G.; Hu, X.; Dent, R. A.; Pierga, J-Y.; Tsurutani, J.; Wildiers, H.; Ricciardi, G. R. R.; Marchio, C.; Penault-Llorca, F.; Bor-Angelier, C.; Andrzejuk-Cwik, A.; Darilay, A.; Matsuo, T.; Shami, R.; Jones, F.; Viale, G. 分享 收藏
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) 6th和7th晚期乳腺癌管理国际共识指南 (ABC指南6和7) Cardoso, Fatima; Paluch-Shimon, Shani; Schumacher-Wulf, Eva; Matos, Leonor; Gelmon, Karen; Aapro, Matti S.; Bajpai, Jyoti; Barrios, Carlos H.; Bergh, Jonas; Bergsten-Nordstrom, Elizabeth; Biganzoli, Laura; Cardoso, Maria Joao; Carey, Lisa A.; Chavez-MacGregor, Mariana; Chidebe, Runcie; Cortes, Javier; Curigliano, Giuseppe; Dent, Rebecca A.; El Saghir, Nagi S.; Eniu, Alexandru; Fallowfield, Lesley; Francis, Prudence A.; Millan, Sandra X. Franco; Gilchrist, Jenny; Gligorov, Joseph; Gradishar, William J.; Haidinger, Renate; Harbeck, Nadia; Hu, Xichun; Kaur, Ranjit; Kiely, Belinda; Kim, Sung-Bae; Koppikar, Smruti; Kuper-Hommel, Marion J. J.; Lecouvet, Frederic E.; Mason, Ginny; Mertz, Shirley A.; Mueller, Volkmar; Myerson, Claire; Neciosup, Silvia; Offersen, Birgitte, V; Ohno, Shinji; Pagani, Olivia; Partridge, Ann H.; Penault-Llorca, Frederique; Prat, Aleix; Rugo, Hope S.; Senkus, Elzbieta; Sledge, George W.; Swain, Sandra M.; Thomssen, Christoph; Vorobiof, Daniel A.; Vuylsteke, Peter; Wiseman, Theresa; Xu, Binghe; Costa, Alberto; Norton, Larry; Winer, Eric P. 分享 收藏
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 study Dent, Rebecca; Cortes, Javier; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Bergh, Jonas; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Untch, Michael; Fasching, Peter A.; Cardoso, Fatima; Haiderali, Amin; Jia, Liyi; Nguyen, Allison Martin; Pan, Wilbur; O'Shaughnessy, Joyce; Schmid, Peter 分享 收藏
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer: Updated event-free survival results from the phase 3 KEYNOTE-522 study Schmid, Peter; Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Harbeck, Nadia; Takahashi, Masato; Foukakis, Theodoros; Mouret-Reynier, Marie-Ange; Ferreira, Marta; Im, Seock-Ah; Cardoso, Fatima; Ding, Yu; Pan, Wilbur; Tryfonidis, Konstantinos; O'Shaughnessy, Joyce 分享 收藏
分享 收藏
Safety evaluation from the KEYNOTE-522 study of neoadjuvant pembrolizumab (or placebo) plus chemotherapy followed by adjuvant pembrolizumab (or placebo) in patients with early triple-negative breast cancer (TNBC) Cortes, Javier; Dent, Rebecca; Pusztai, Lajos; McArthur, Heather; Kuemmel, Sherko; Denkert, Carsten; Park, Yeon Hee; Hui, Rina; Takahashi, Masato; Barrios, Carlos; Zhu, Yalin; Zhang, Xiaoli; Pan, Wilbur; Karantza, Vassiliki; O'Shaughnessy, Joyce; Schmid, Peter 分享 收藏
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522 5 Pusztai, L.; Denkert, C.; O'Shaughnessy, J.; Cortes, J.; Dent, R.; Mcarthur, H.; Kuemmel, S.; Bergh, J.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Zhu, Y.; Pan, W.; Tryfonidis, K.; Schmid, P. 分享 收藏
分享 收藏
The Prognostic Value of CD39 as a Marker of Tumor-Specific T Cells in Triple-Negative Breast Cancer in Asian Women CD39作为肿瘤特异性T细胞标志物在亚洲女性三阴性乳腺癌中的预后价值 Meng, Jia; Tan, Jing Ying Tira; Joseph, Craig Ryan; Ye, Jiangfeng; Lim, Jeffrey Chun Tatt; Goh, Denise; Xue, Yuezhen; Lim, Xinru; Koh, Valerie Cui Yun; Wee, Felicia; Tay, Timothy Kwang Yong; Chan, Jaason Yongsheng; Ng, Cedric Chuan Young; Iqbal, Jabed; Lau, Mai Chan; Lim, Hsuen Elaine; Toh, Han Chong; Teh, Bin Tean; Dent, Rebecca Alexandra; Tan, Puay Hoon; Yeong, Joe Poh Sheng 分享 收藏
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study pembrolizumab与化疗对转移性三阴性乳腺癌患者健康相关生活质量的影响: 3期随机主题119研究的结果 Schmid, Peter; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Munoz-Couselo, Eva; Lee, Keun Seok; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Mejia, Jaime A.; Zhou, Xuan; Haiderali, Amin; Nguyen, Allison Martin; Cortes, Javier; Winer, Eric P. 分享 收藏
Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP) Lee, S. C.; Park, Y. H.; Singer, C.; Balmana, J.; Dent, R. A.; Tan, V. K.; Sari, N. A. M.; Yusof, M. Md; Que, F. V. F.; Lu, Y-S.; Parinyanitikul, N.; Pham, C. P.; Taib, N. A. M.; Kong, S-Y.; Antill, Y.; Kim, H. J. 分享 收藏
Phase III study of neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for early-stage triple-negative breast cancer (TNBC): KEYNOTE-522 Korean subgroup analysis Park, Y. H.; Im, S-A.; Ahn, J-H.; Kim, M. H.; Cortes, J.; Dent, R. A.; Pusztai, L.; McArthur, H. L.; Kummel, S.; Denkert, C.; O'Shaughnessy, J.; Mouret-Reynier, M-A.; Ferreira, M. I. R.; Cortes, M. Gion; Boileau, J-F.; Hui, R.; Zhu, Y.; Pan, W.; Karantza, V. V.; Schmid, P. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
Annals of Oncology.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏
OAAI